Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling ...

Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...

The general mood among these heavyweight investors is divided, with 45% leaning bullish and 50% bearish. Among these notable ...

Brands like Kourtney Kardashian's Lemme are claiming to provide the same benefits as GLP-1 medications like Ozempic, Wegovy, ...

It is not clear yet if the oral drug works ... Chan often prescribes off-label diabetes medications like metformin. Some doctors who treat PCOS, including OB-GYNs or endocrinologists, have also begun ...

Image credit Weight loss is an incredible journey; if you’ve been through it, you know how frustrating and overwhelmin ...

(HealthDay News) — Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with the risk for retained gastric contents and inadequate bowel preparation during endoscopic procedures, ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

New drugs from public and private companies are ... These new challengers are anticipated to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion ...

He pointed to the nearly 1,200 medicines in development – including 62 for heart disease, 99 for breast cancer (an all-time ...

With most of the other drugs the risk is less than 1% and usually less than 0.1% of those taking the medication will develop drug-induced lupus.

Dave Ramsey, a bestselling author, radio host and economic consultant whose net worth is believed to be between $150million-$200 million, spoke to the former president and Republican nominee on ...